(Q58022064)

inferred from title

hepatocellular carcinoma

1 reference

1

Josep M. Llovet

0 references

author name string

Margarita Sala

2

0 references

Lluís Castells

3

0 references

Yanette Suarez

4

0 references

Ramon Vilana

5

0 references

Lluís Bianchi

6

0 references

Carmen Ayuso

7

0 references

Víctor Vargas

8

0 references

Joan Rodés

9

0 references

Jordi Bruix

Liver transplantation for small hepatocellular carcinoma: The tumor-node-metastasis classification does not have prognostic power

10

0 references

language of work or name

English

0 references

publication date

January 2000

0 references

published in

Hepatology

0 references

volume

31

0 references

issue

1

0 references

page(s)

54-58

0 references

cites work

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310111

Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310111

Review article: Overview of medical treatments in unresectable hepatocellular carcinoma--an impossible meta-analysis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310111

Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310111

Interferons in the treatment of human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310111

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310111

5-Fluorouracil and alpha-interferon in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310111

Hepatic arterial infusion of floxuridine, leucovorin, doxorubicin, and cisplatin for hepatocellular carcinoma: effects of hepatitis B and C viral infection on drug toxicity and patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310111

Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310111

Renal function abnormalities, prostaglandins, and effects of nonsteroidal anti-inflammatory drugs in cirrhosis with ascites. An overview with emphasis on pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310111

Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310111

Side effects of α interferon in chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310111

Recombinant interferon-α in inoperable hepatocellular carcinoma: A randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310111

Rising incidence of hepatocellular carcinoma in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310111

7 January 2021

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310111

7 January 2021

Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310111

7 January 2021

Treatment of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310111

7 January 2021

Treatment of hepatocellular carcinoma with recombinant leucocyte interferon: a pilot study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310111

7 January 2021

A prospective trial of recombinant human interferon alpha 2B in previously untreated patients with hepatocellular carcinoma. The Gastrointestinal Tumor Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310111

7 January 2021

Low serum alpha-fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5-fu and interferon-alpha-2b

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310111

7 January 2021

Combined doxorubicin and alpha-interferon therapy of advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310111

7 January 2021

Clinical pilot study of intrahepatic arterial chemotherapy with methotrexate, 5-fluorouracil, cisplatin and subcutaneous interferon-alpha-2b for patients with locally advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310111

7 January 2021

Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310111

7 January 2021

Prognosis of hepatocellular carcinoma: the BCLC staging classification

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310111

7 January 2021

Treatment of hepatocellular carcinoma with tamoxifen: A double-blind placebo-controlled trial in 120 patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310111

7 January 2021

Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310111

7 January 2021

Performance status assessment in cancer patients. An inter-observer variability study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310111

7 January 2021

Transection of the oesophagus for bleeding oesophageal varices

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310111

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310111

7 January 2021

Durable clinical and pathologic response of hepatocellular carcinoma to systemic and hepatic arterial administration of platinol, recombinant interferon alpha 2B, doxorubicin, and 5-fluorouracil: a communication

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310111

7 January 2021